# Discussion

## Conclusion {-}

```{r}
caption <- "**Preliminary map of the evidence and future directions in biomarker development.** The Sankey diagram presents a summary of the methodological parameters and contexts of use (COUs) across the 432 potential biomarkers in the systematic review. Moving forward, expert consensus and meta- and mega-analyses may be used to facilitate harmonization and the development of optimal FDCR biomarkers which would undergo analytical and clinical validation and cost-benefit analysis before regulatory qualification for drug development or clinical use."
```

```{r fig.cap=caption}
knitr::include_graphics(path = "./fig/figure-8.png")
```